SpaceX vs Rocket Lab: What's the Better Buy Right Now?

SpaceX and Rocket Lab are framed as expensive but compelling space stocks, with SpaceX favored due to its larger, more diversified growth opportunities and stronger retail interest. SpaceX is cited as trading at more than 100 times revenue despite over $4 billion in losses in Q1, while Rocket Lab trades at about 80 times revenue with $183 million in trailing-12-month losses and quarterly revenue above $200 million, up nearly 64% year over year. Rocket Lab's upcoming Neutron rocket launch and $1.3 billion in U.S. Space Development Agency contracts are highlighted as potential catalysts.

Analysis

The key market dynamic here is not just relative quality, but attention flow. A high-profile public listing in the space complex tends to re-rate the whole basket first, and the smallest names with the cleanest operating leverage usually respond fastest; that makes RKLB the more elastic expression of a sector bid even if it is not the highest-quality asset. In that setup, the second-order winner is the sub-scale supplier ecosystem around launch, guidance, avionics, and ground systems, while the loser is any defense/space prime where incremental enthusiasm gets diluted across larger, slower-growth revenue bases.

RKLB’s setup is more event-driven than the article implies. The Neutron catalyst creates a binary window: a clean test/launch sequence can force multiple expansion over weeks, but any slip will likely compress the stock more than the underlying business, because the current valuation already capitalizes a lot of future capability. The market is effectively paying for a de-risking event in the next 1-2 quarters; if that event moves to the right, the stock can derate even if quarterly revenue keeps growing.

The contrarian angle is that the consensus may be underpricing how fragile sentiment is in capital-intensive space names. These are not software-like “growth at any price” stories; they require repeated access to capital, flawless execution, and a credible path to unit economics. If funding conditions tighten or launch cadence disappoints, the multiple can compress much faster than revenue can catch up, especially for RKLB where the market is implicitly underwriting the next leg of product evolution.

From a competitive standpoint, the real threat is not only other launch providers but also buyers delaying procurement while waiting for Neutron to prove payload economics. That can create a temporary air pocket in bookings even if long-term demand is intact. In that sense, the most attractive trade is to own the catalyst but hedge the execution risk rather than making a clean directional bet.

Key Decisions for Investors

• Go long RKLB into Neutron-related milestones over the next 1-2 quarters; use a tight stop if launch timelines slip. Upside is a sharp multiple re-rating on de-risking, while downside is a fast compression if execution disappoints.
• Consider a call spread on RKLB rather than outright stock to express the catalyst with defined risk. Best use case: event window over the next 3-6 months where implied volatility may understate binary launch risk.
• If already long space beta, pair RKLB long against a higher-quality diversified aerospace/defense short or underweight to isolate Neutron upside from broader sector sentiment. The trade works if the market rewards pure catalysts more than diversified exposure.
• Take profits into any post-launch spike rather than waiting for full commercial proof. The first move is likely sentiment-driven; the second move depends on sustained cadence and backlog conversion, which will take longer.